Dose-Escalation Safety and Pharmacokinetic Study of ATX-101

Phase 1, Open-Label, Dose-Escalation Safety and Pharmacokinetic Study of ATX-101 (Sodium Deoxycholate for Injection) Following Subcutaneous Injections in the Submental Area

The purpose of this research is to evaluate the safety and pharmacokinetic profile of single doses of ATX-101

This is a single center, open-label, dose-escalation study in which subjects will receive 4 different dosage concentrations (3 dosing paradigms) of ATX-101 in a single dosing session.

Inclusion Criteria:

• Healthy males or nonpregnant females
• Age 18 to 65
• Sufficient submental fat for injections
• Signed informed consent

Exclusion Criteria:

• Prior interventions in the chin or neck area
• History or presence of drug or alcohol abuse
• Treatment with an investigational agent within 30 days before the dose